Kent Marine Superbuffer-DKH Super sale Kent Marine Superbuffer-DKH Super sale /Homorelaps187622.html,laagvlieger.x24hr.com,Superbuffer-DKH,Kent,$24,Marine,Pet Supplies , Fish Aquatic Pets , Aquarium Water Treatments $24 Kent Marine Superbuffer-DKH Pet Supplies Fish Aquatic Pets Aquarium Water Treatments $24 Kent Marine Superbuffer-DKH Pet Supplies Fish Aquatic Pets Aquarium Water Treatments /Homorelaps187622.html,laagvlieger.x24hr.com,Superbuffer-DKH,Kent,$24,Marine,Pet Supplies , Fish Aquatic Pets , Aquarium Water Treatments

Kent Marine Superbuffer-DKH Super sale Nashville-Davidson Mall

Kent Marine Superbuffer-DKH

$24

Kent Marine Superbuffer-DKH

|||

Product description

Size:1.10-Pound Jar  |  Product Packaging:Standard Packaging

Kent Superbuffer-DKH is a specially formulated pH buffer and alkalinity or carbonate hardness (KH) builder, designed to adjust the pH of saltwater aquariums to the range of 8.0 to 8.3 and build the KH. Superbuffer-DKH is the finest buffer available for either fish only or reef type marine aquariums and is designed to mix clear with little or no cloudiness or precipitation. Will not flake on your corals as other competing products can. Compatible with and designed for use with Kalkwasser Mix, Concentrated Liquid Calcium, or Turbo-Calcium by Kent Marine. Kent Marine was established by aquatic hobbyists who saw a need for products that aid the user in creating the most natural enclosed marine and freshwater environment possible. From vitamin and mineral supplements to nutritional products and filter media, Kent aquarium set the benchmark and was one of the first in the aquatic industry to provide these unique solutions. For the past 15-year, Kent Marine products have helped aquarists create healthy aquariums. Through continuous research, testing and development, new products like salt mix, scrapers and Kent RO filters were brought into the Kent Marine family.

Kent Marine Superbuffer-DKH

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA